Literature DB >> 34421145

Lithium-Induced Hyperparathyroidism: An Ill-defined Territory.

Vishwanath Pattan1, Balwinder Singh1, Sahar S Abdelmoneim1, Chaitra Gopinath1, Vishnu Sundaresh1.   

Abstract

Lithium is the gold standard treatment for bipolar disorder. Studies have shown an association between lithium and hyperparathyroidism. However, there is limited data regarding the management of lithium-induced hyperparathyroidism. We present a clinical conundrum which physicians frequently encounter-an excellent lithium responder refractory to other treatments who developed lithium-induced hyperparathyroidism. Medical treatment with cinacalcet was successful in management of hyperparathyroidism without discontinuing lithium maintenance therapy.
Copyright © 1964–2021 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  bipolar disorder; cinacalcet; hypercalcemia; hyperparathyroidism; lithium

Mesh:

Substances:

Year:  2021        PMID: 34421145      PMCID: PMC8374931     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  22 in total

1.  Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders.

Authors:  Ross J Baldessarini; Leslie Leahy; Stephen Arcona; Douglas Gause; Winnie Zhang; John Hennen
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

2.  Lithium continuation for a patient with bipolar disorder and chronic kidney disease.

Authors:  Balwinder Singh; Nicolás A Núñez; Lisa Schock; Boney Joseph; Bradley Kohoutek; James L Roerig
Journal:  Bipolar Disord       Date:  2020-04-20       Impact factor: 6.744

Review 3.  Cinacalcet hydrochloride.

Authors:  Julia A Barman Balfour; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.

Authors:  T Suppes; R J Baldessarini; G L Faedda; M Tohen
Journal:  Arch Gen Psychiatry       Date:  1991-12

Review 5.  Hyperparathyroidism associated with treatment of manic-depressive disorders by lithium.

Authors:  J Nordenström; K Strigård; L Perbeck; J Willems; M Bågedahl-Strindlund; J Linder
Journal:  Eur J Surg       Date:  1992-04

6.  Lithium-associated hyperparathyroidism and hypercalcaemia: a case-control cross-sectional study.

Authors:  Umberto Albert; David De Cori; Andrea Aguglia; Francesca Barbaro; Fabio Lanfranco; Filippo Bogetto; Giuseppe Maina
Journal:  J Affect Disord       Date:  2013-07-17       Impact factor: 4.839

7.  Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study.

Authors:  T W Mak; C C Shek; C C Chow; Y K Wing; S Lee
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

8.  Lithium-associated primary hyperparathyroidism complicated by nephrogenic diabetes insipidus.

Authors:  Nihat Aksakal; Candaş Erçetin; Beyza Özçınar; Ferihan Aral; Yeşim Erbil
Journal:  Ulus Cerrahi Derg       Date:  2015-09-01

9.  Spectrum of lithium induced thyroid abnormalities: a current perspective.

Authors:  Davis Kibirige; Kenneth Luzinda; Richard Ssekitoleko
Journal:  Thyroid Res       Date:  2013-02-07

10.  Lithium-Associated Hypercalcemia: Pathophysiology, Prevalence, Management.

Authors:  Adrian D Meehan; Ruzan Udumyan; Mathias Kardell; Mikael Landén; Johannes Järhult; Göran Wallin
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.